Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: A practical approach

Dermatologic Surgery

Volumn 38, Issue 10, 2012, Pages 1604-1621

  Ritchie, Simon A ^a   Patel, Manisha J ^b   Miller, Stanley J ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; AZATHIOPRINE; CAPECITABINE; CELECOXIB; CYCLOSPORIN A; DICLOFENAC; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETRETIN; EVEROLIMUS; FLUOROURACIL; IMIQUIMOD; ISOTRETINOIN; LIQUID NITROGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RAPAMYCIN; SUNSCREEN; TACROLIMUS;

ACNE; ACTINIC KERATOSIS; ALOPECIA; ANKLE EDEMA; APHTHOUS ULCER; APPLICATION SITE BURNING; APPLICATION SITE CRUSTING; APPLICATION SITE ERYTHEMA; APPLICATION SITE INFLAMMATION; ASEPTIC NECROSIS; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENICITY; CLINICAL EVALUATION; CONTACT ALLERGY; DERMATOLOGIST; DIARRHEA; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRY SKIN; EROSION; ERYTHEMA; FATIGUE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; GRAFT RECIPIENT; HAND FOOT SYNDROME; HEALTH EDUCATION; HEPATITIS; HIGH RISK PATIENT; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOCOMPROMISED PATIENT; INFECTION; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LOADING DRUG DOSE; MORBIDITY; MUCOSA INFLAMMATION; MUCOSAL DRYNESS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROTECTIVE CLOTHING; PROTEINURIA; PUSTULE; REVIEW; RISK ASSESSMENT; SKIN BIOPSY; SKIN BURNING SENSATION; SKIN CARCINOMA; SKIN CRUSTING; SKIN DISEASE; SKIN EXAMINATION; SKIN FISSURE; SKIN PROTECTION; SUN EXPOSURE; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; TUMOR VOLUME; WOUND HEALING IMPAIRMENT; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KERATOSIS, ACTINIC; ORGAN TRANSPLANTATION; PATIENT CARE TEAM; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 84867098747     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02452.x     Document Type: Review

References (113)

1. Penn I, Halgrimson CG, Starzl TE,. De novo malignant tumors in organ transplant recipients. Transplant Proc 1971; 3: 773-8.
2. Geusau A, Dunkler D, Messeritsch E, Sandor N, et al. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy. Int J Dermatol 2008; 47: 918-25.
3. Jensen P, Hansen S, Moller B, Leivestad T, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-86.
4. Adami J, Gabel H, Lindelof B, Ekstrom K, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003; 89: 1221-7.
5. Wisgerhof HC, Edelbroek JR, de Fijter JW, Feltkamp MC, et al. Trends of skin diseases in organ-transplant recipients transplanted between 1966 and 2006: a cohort study with follow-up between 1994 and 2006. Br J Dermatol 2010; 162: 390-6.
6. Criscione VD, Weinstock MA, Naylor MF, Luque C, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523-30.
7. Sheil AG, Disney AP, Mathew TH, Amiss N,. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-4.
8. Buell JF, Hanaway MJ, Thomas M, Alloway RR, et al. Skin cancer following transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005; 37: 962-3.
9. Martinez JC, Otley CC, Stasko T, Euvrard S, et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multicenter collaborative study. Arch Dermatol 2003; 139: 301-6.
10. Lott DG, Manz R, Koch C, Lorenz RR,. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010; 90: 683-7.
11. Wolfe RA, Roys EC, Merion RM,. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 961-72.
12. Yusen RD, Shearon TH, Qian Y, Kotloff R, et al. Lung transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1047-68.
13. Mackenzie KA, Wells JE, Lynn KL, Simcock JW, et al. First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. Nephrol Dial Transplant 2010; 25: 300-6.
14. Euvrard S, Kanitakis J, Decullier E, Butnaru AC, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093-100.
15. Otley CC,. Pretransplantation dermatologic screening and prophylaxis. In:, Group SC, editor. Skin Cancer After Transplantation. New York: Spring Science+Business Media, LLC; 2009. pp. 391-404.
16. Stasko T, Brown MD, Carucci JA, Euvrard S, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg 2004; 30: 642-50.
17. Hofbauer GF, Bouwes Bavinck JN, Euvrard S,. Organ transplantation and skin cancer: basic problems and new perspectives. Exp Dermatol 2010; 19: 473-82.
18. Miller SJ,. Defining, treating, and studying very high-risk cutaneous squamous cell carcinomas. Arch Dermatol 2010; 146: 1292-5.
19. Cook BA, Gravely AA, Nelson DB, Warshaw EM,. Is tenderness a reliable predictor for differentiating squamous cell carcinomas from actinic keratoses? J Am Acad Dermatol 2011; 65: 211-2.
20. Hofbauer GF, Gjersvik P, Bouwes Bavinck JN,. Report on the tenth annual meeting of SCOPE (Skin Care in Organ Transplant Recipients in Europe). J Invest Dermatol 2011; 131: 1192-3.
21. Otley CC, Berg D, Ulrich C, Stasko T, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. Br J Dermatol 2006; 154: 395-400.
22. Brantsch KD, Meisner C, Schonfisch B, Trilling B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-20.
23. Clinical and Histologic Findings Associated with SCC Recurrence. Available from: www.nccn.org. Accessed December 3, 2011.
24. Cutaneous squamous cell carcinomas and other cutaneous carcinomas. In:, Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual, 7th edition. New York: Springer Verlag; 2010. pp. 306.
25. Christenson LJ, Cherikh WS, Otley CC, Salasche SJ, et al. Allograft and overall survival of patients with posttransplant skin cancer. Dermatol Surg 2011; 37: 183-91.
26. de Graaf YG, Rebel H, Elghalbzouri A, Cramers P, et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008; 17: 349-55.
27. Hofbauer GF, Anliker M, Arnold A, Binet I, et al. Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly 2009; 139: 407-15.
28. Miller SJ, Lavker RM, Sun TT,. Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 2005; 1756: 25-52.
29. Slaughter DP, Southwick HW, Smejkal W,. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
30. Odocha O,. Post-transplant malignancies in minority populations. In Vivo 1996; 10: 237-40.
31. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S,. Skin cancer in organ transplant recipientsâwhere do we stand today? Am J Transplant 2008; 8: 2192-8.
32. Moloney FJ, Kelly PO, Kay EW, Conlon P, et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004; 30: 674-8.
33. Wulff BC, Kusewitt DF, VanBuskirk AM, Thomas-Ahner JM, et al. Sirolimus reduces the incidence and progression of UVB-induced skin cancer in SKH mice even with co-administration of cyclosporine A. J Invest Dermatol 2008; 128: 2467-73.
34. O'Donovan P, Perrett CM, Zhang X, Montaner B, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-4.
35. Kelly GE, Meikle W, Sheil AG,. Effects of immunosuppressive therapy on the induction of skin tumors by ultraviolet irradiation in hairless mice. Transplantation 1987; 44: 429-34.
36. Ulrich C, Jurgensen JS, Degen A, Hackethal M, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 (Suppl 3): 78-84.
37. Terhorst D, Drecoll U, Stockfleth E, Ulrich C,. Organ transplant recipients and skin cancer: assessment of risk factors with focus on sun exposure. Br J Dermatol 2009; 161 (Suppl 3): 85-9.
38. Brown VL, Atkins CL, Ghali L, Cerio R, et al. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol 2005; 141: 985-93.
39. Ulrich C, Bichel J, Euvrard S, Guidi B, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157 (Suppl 2): 25-31.
40. Smith KJ, Germain M, Skelton H,. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27: 561-4.
41. Perrett CM, McGregor JM, Warwick J, Karran P, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol 2007; 156: 320-8.
42. de Graaf YG, Kennedy C, Wolterbeek R, Collen AF, et al. Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol 2006; 126: 569-74.
43. Wennberg AM, Stenquist B, Stockfleth E, Keohane S, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation 2008; 86: 423-9.
44. Dragieva G, Prinz BM, Hafner J, Dummer R, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004; 151: 196-200.
45. Piaserico S, Belloni Fortina A, Rigotti P, Rossi B, et al. Topical photodynamic therapy of actinic keratosis in renal transplant recipients. Transplant Proc 2007; 39: 1847-50.
46. Willey A, Mehta S, Lee PK,. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg 2009; 36: 652-8.
47. Kienzler JL, Gold M, Nollevaux F,. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010; 50: 50-61.
48. Laine L, Goldkind L, Curtis SP, Connors LG, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol 2009; 104: 356-62.
49. Ulrich C, Hackethal M, Ulrich M, Howorka A, et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007; 156 (Suppl 3): 40-2.
50. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, et al. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol 2010; 20: 482-8.
51. Mann M, Berk DR, Petersen J,. Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J Drugs Dermatol 2008; 7: 685-8.
52. Mattison LK, Soong R, Diasio RB,. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002; 3: 485-92.
53. Otley CC, Stasko T, Tope WD, Lebwohl M,. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006; 32: 562-8.
54. Chen K, Craig JC, Shumack S,. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152: 518-23.
55. de Graaf YG, Euvrard S, Bouwes Bavinck JN,. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004; 30: 656-61.
56. Martinez JC, Otley CC, Euvrard S, Arpey CJ, et al. Complications of systemic retinoid therapy in organ transplant recipients with squamous cell carcinoma. Dermatol Surg 2004; 30: 662-6.
57. Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-8.
58. Harwood CA, Leedham-Green M, Leigh IM, Proby CM,. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005; 141: 456-64.
59. George R, Weightman W, Russ GR, Bannister KM, et al. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol 2002; 43: 269-73.
60. Jirakulaporn T, Endrizzi B, Lindgren B, Mathew J, et al. Capecitabine for skin cancer prevention in solid organ transplant recipients. Clin Transplant 2011; 25: 541-8.
61. Kalyankrishna S, Grandis JR,. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-72.
62. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2: 345-51.
63. Miller K, Sherman W, Ratner D,. Complete clinical response to cetuximab in a patient with metastatic cutaneous squamous cell carcinoma. Dermatol Surg 2010; 36: 2069-74.
64. Suen JK, Bressler L, Shord SS, Warso M, et al. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007; 18: 827-9.
65. Sano D, Matsumoto F, Valdecanas DR, Zhao M, et al. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res 2010; 17: 1815-27.
66. Leard LE, Cho BK, Jones KD, Hays SR, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant 2007; 26: 1340-4.
67. Neuburg M,. Transplant-associated skin cancer: role of reducing immunosuppression. J Natl Compr Canc Netw 2007; 5: 541-9.
68. Otley CC, Maragh SL,. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005; 31: 163-8.
69. Giese T, Sommerer C, Zeier M, Meuer S,. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol 2009; 132: 305-11.
70. Kirk AD, Mannon RB, Swanson SJ, Hale DA,. Strategies for minimizing immunosuppression in kidney transplantation. Transpl Int 2005; 18: 2-14.
71. Otley CC, Griffin MD, Charlton MR, Edwards BS, et al. Reduction of immunosuppression for transplant-associated skin cancer: thresholds and risks. Br J Dermatol 2007; 157: 1183-8.
72. Giese T, Zeier M, Schemmer P, Uhl W, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004; 77: 339-44.
73. Sommerer C, Konstandin M, Dengler T, Schmidt J, et al. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006; 82: 1280-5.
74. Sommerer C, Hartschuh W, Enk A, Meuer S, et al. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008; 22: 549-54.
75. Sommerer C, Giese T, Schmidt J, Meuer S, et al. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 2008; 85: 15-21.
76. Sommerer C, Zeier M, Meuer S, Giese T,. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010; 89: 1417-23.
77. Vadnerkar A, Nguyen MH, Mitsani D, Crespo M, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29: 1240-4.
78. Ibrahim SF, Singer JP, Arron ST,. Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole. Dermatol Surg 2010; 36: 1752-5.
79. Euvrard S, Boissonnat P, Roussoulieres A, Kanitakis J, et al. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients. Transpl Int 2010; 23: 855-7.
80. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-42.
81. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-75.
82. Salgo R, Gossmann J, Schofer H, Kachel HG, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385-93.
83. Ponticelli C, Scolari MP,. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review. Transplant Proc 2010; 42: 2205-8.
84. Euvrard S, Verschoore M, Touraine JL, Dureau G, et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992; 340: 48-9.
85. Sachs DL, Kang S, Hammerberg C, Helfrich Y, et al. Topical fluorouracil for actinic keratoses and photoaging: a clinical and molecular analysis. Arch Dermatol 2009; 145: 659-66.
86. Askew DA, Mickan SM, Soyer HP, Wilkinson D,. Effectiveness of 5-fluorouracil treatment for actinic keratosisâa systematic review of randomized controlled trials. Int J Dermatol 2009; 48: 453-63.
87. Morton C, Horn M, Leman J, Tack B, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006; 142: 729-35.
88. Salim A, Leman JA, McColl JH, Chapman R, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003; 148: 539-43.
89. Patel GK, Goodwin R, Chawla M, Laidler P, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2006; 54: 1025-32.
90. Peris K, Micantonio T, Fargnoli MC, Lozzi GP, et al. Imiquimod 5% cream in the treatment of Bowen's disease and invasive squamous cell carcinoma. J Am Acad Dermatol 2006; 55: 324-7.
91. Dragieva G, Hafner J, Dummer R, Schmid-Grendelmeier P, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004; 77: 115-21.
92. de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, et al. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49: 407-12.
93. Levine N, Moon TE, Cartmel B, Bangert JL, et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997; 6: 957-61.
94. Elmets CA, Viner JL, Pentland AP, Cantrell W, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102: 1835-44.
95. Einollahi B, Nemati E, Lessan-Pezeshki M, Simforoosh N, et al. Skin cancer after renal transplantation: results of a multicenter study in Iran. Ann Transplant 2010; 15: 44-50.
96. Ingvar A, Smedby KE, Lindelof B, Fernberg P, et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 2010; 25: 2764-71.
97. Hofbauer GF, Attard NR, Harwood CA, McGregor JM, et al. Reversal of UVA Skin Photosensitivity and DNA Damage in Kidney Transplant Recipients by Replacing Azathioprine. Am J Transplant 2012; 12: 218-25.
98. Durando B, Reichel J,. The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients. Dermatol Ther 2005; 18: 1-11.
99. Duncan FJ, Wulff BC, Tober KL, Ferketich AK, et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. Am J Transplant 2007; 7: 2693-703.
100. Guba M, Graeb C, Jauch KW, Geissler EK,. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777-82.
101. Koehl GE, Wagner F, Stoeltzing O, Lang SA, et al. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 2007; 83: 607-14.
102. Eisen HJ, Kobashigawa J, Keogh A, Bourge R, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517-25.
103. Wang K, Zhang H, Li Y, Wei Q, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004; 36: 2068-70.
104. Dantal J, Hourmant M, Cantarovich D, Giral M, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-8.
105. Wu X, Nguyen BC, Dziunycz P, Chang S, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010; 465: 368-72.
106. Han W, Ming M, He TC, He YY,. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem 2010; 285: 11369-77.
107. Walsh SB, Xu J, Xu H, Kurundkar AR, et al. Cyclosporine A mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFbeta signaling pathway. Mol Carcinog 2011; 50: 516-27.
108. Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, et al. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas. Anticancer Res 2009; 29: 1927-32.
109. Yarosh DB, Pena AV, Nay SL, Canning MT, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-5.
110. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.
111. Ballou LM, Lin RZ,. Rapamycin and mTOR kinase inhibitors. J Chem Biol 2008; 1: 27-36.
112. 2009 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Tables 5.6d and 5.6e. U.S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Rockville, MD.
113. Johnson MR, Meyer KH, Haft J, Kinder D, et al. Heart transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1035-46.